Lipocine Operating Income Over Time
| LPCN Stock | USD 9.80 0.43 4.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lipocine Performance and Lipocine Correlation. Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.02) | Revenue Per Share | Quarterly Revenue Growth 5.954 | Return On Assets | Return On Equity |
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Lipocine and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | 77.9 M | 1.3 B | 989 M | 1.2 B | 1.3 B | 1.7 B | 2 B | 1.7 B | 1.9 B | 2 B | 2.7 B | 2.8 B | 2.4 B | 3 B | 3.6 B | 4.2 B | 4.4 B |
| REGN | (3.3 M) | (205.2 M) | 457.7 M | 760 M | 838.4 M | 1.3 B | 1.3 B | 2.1 B | 2.5 B | 2.2 B | 3.6 B | 8.9 B | 5.4 B | 4 B | 4 B | 3.6 B | 3.8 B |
| IDXX | 2.6 M | 236.2 M | 262.6 M | 266.8 M | 260.3 M | 299.9 M | 350.2 M | 413 M | 491.3 M | 552.8 M | 694.5 M | 932 M | 898.8 M | 1.1 B | 1.1 B | 1.4 B | 1.4 B |
| HLN | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 1.6 B | 1.6 B | 1.8 B | 2 B | 2.2 B | 2.5 B | 1.9 B |
| CI | (854.9 M) | 1.9 B | 2.9 B | 32.4 B | 11.6 B | 12.4 B | 3.1 B | 3.9 B | 4.2 B | 8.1 B | 8.2 B | 7.9 B | 8.4 B | 8.5 B | 9.4 B | 9.1 B | 9.6 B |
| ELV | 11.1 B | 4.5 B | 4.4 B | 4.7 B | 5.1 B | 5.4 B | 5.4 B | 5 B | 5.8 B | 6.7 B | 7.7 B | 8.9 B | 8.5 B | 8.7 B | 8.9 B | 8.1 B | 6.8 B |
| BDX | 137.7 M | 1.6 B | 1.3 B | 1.6 B | 1.1 B | 1.4 B | 1.5 B | 1.5 B | 1.8 B | 912 M | 2.2 B | 2.3 B | 2.1 B | 2.4 B | 2.6 B | 3 B | 3.1 B |
| ARGX | (4.7 M) | (4.7 M) | (13.3 M) | (8.6 M) | (13.1 M) | (17.1 M) | (22.5 M) | (27.5 M) | (93.6 M) | (198.9 M) | (477.6 M) | (348.7 M) | (720.3 M) | (425 M) | (21.7 M) | (19.5 M) | (20.5 M) |
Lipocine and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Operating Income description
Operating Income is the amount of profit realized from Lipocine operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lipocine is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Lipocine | LPCN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 675 Arapeen Drive, |
| Exchange | NASDAQ Exchange |
USD 9.8
Check out Lipocine Performance and Lipocine Correlation. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Lipocine technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.